Literature DB >> 2613378

Clinical and laboratory signs of reperfusion: are they reliable?

J C Nicolau1, A M Lorga, S A Garzon, J L Jacob, N C Machado, A J Bellini, O T Greco, L A Marques, D M Braile.   

Abstract

We studied 101 patients (88 men and 13 women, mean age 54.5 +/- 10 years) who arrived at the hospital during the first 6 hours of acute myocardial infarction evolution. Our objective was to assess the reliability of clinical and laboratory signs of recanalization using intravenous streptokinase as a thrombolytic agent. The mean time between the beginning of infusion and coronary arteriography was 53.83 +/- 43 hours. The positive predictive values for pain, arrhythmia, ST segment and enzymes were 97.9%, 94.2%, 91.8% and 90.8%, respectively; the negative predictive values were 46.8%, 40.8%, 37.2%, and 50% in the same order. Sensitivity was 65.7%, 62.8%, 58.4% and 77.6% and specificity 95.6%, 86.9%, 82.6% and 73.9%, respectively. The positive predictive value, calculated on the basis of the presence of each variable alone or in association showed a probability of recanalization of 76.9% for one sign, 84% for two, 96.3% for three and 100% for all four. When we compared the positive predictive values of each variable according to the interval between the beginning of pain and admission to the hospital (during the first 3 hours or between 3 and 6 hours) our results were 100%/94% for pain (P = NS), 97%/88% for arrhythmia (P = NS), 100%/75% for ST segment (P = 0.004), and 97%/80% for enzymes (P = 0.019). The same analysis applied to negative predictive values showing 22%/62% (P = 0.007), 17%/55% (P = 0.008), 21%/47% (P = NS), 27%/61% (P = NS) for pain, arrhythmia, ST segment and enzymes, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2613378     DOI: 10.1016/0167-5273(89)90221-0

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  8 in total

Review 1.  The role of coronary angioplasty and stenting in acute myocardial infarction.

Authors:  A Brodison; R S More; A Chauhan
Journal:  Postgrad Med J       Date:  1999-10       Impact factor: 2.401

Review 2.  The use of the electrocardiogram to identify epicardial coronary and tissue reperfusion in acute myocardial infarction.

Authors:  M Vaturi; Y Birnbaum
Journal:  J Thromb Thrombolysis       Date:  2000-10       Impact factor: 2.300

3.  Antistreptokinase antibodies and the response to thrombolysis with streptokinase in patients with acute ST elevation myocardial infarction.

Authors:  M S K Subhendu; Oommen K George; John A Jude Prakash
Journal:  Heart Asia       Date:  2012-01-01

4.  Failure of thrombolysis by streptokinase: detection with a simple electrocardiographic method.

Authors:  A G Sutton; P G Campbell; D J Price; E D Grech; J A Hall; A Davies; M J Stewart; M A de Belder
Journal:  Heart       Date:  2000-08       Impact factor: 5.994

Review 5.  Criteria for drug usage review of thrombolytics in acute myocardial infarction.

Authors:  S McGlynn
Journal:  Pharmacoeconomics       Date:  1995-01       Impact factor: 4.981

6.  One year results of the Middlesbrough early revascularisation to limit infarction (MERLIN) trial.

Authors:  A G C Sutton; P G Campbell; R Graham; D J A Price; J C Gray; E D Grech; J A Hall; A A Harcombe; R A Wright; R H Smith; J J Murphy; A Shyam-Sundar; M J Stewart; A Davies; N J Linker; M A de Belder
Journal:  Heart       Date:  2005-10       Impact factor: 5.994

Review 7.  The use of the electrocardiogram to identify epicardial coronary and tissue reperfusion in acute myocardial infarction.

Authors:  M Vaturi MD; Y Birnbaum MD
Journal:  J Thromb Thrombolysis       Date:  2000-08       Impact factor: 2.300

8.  Defibrotide versus heparin in the prevention of coronary reocclusion after thrombolysis in acute myocardial infarction.

Authors:  M Tubaro; G Mattioli; F Matta; C Cappello; E Natale; R Ricci; P Gerardi; F Milazzotto
Journal:  Cardiovasc Drugs Ther       Date:  1993-11       Impact factor: 3.727

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.